[PDF][PDF] Point mutation of the PSMB5 gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma …
S Lu, J Yang, X Song, S Gong, H Zhou, L Guo… - … of Pharmacology and …, 2008 - Citeseer
In order to study the mechanism of acquired resistance to bortezomib, a new antitumor drug
that is the first therapeutic proteasome inhibitor, we established a series of bortezomib …
that is the first therapeutic proteasome inhibitor, we established a series of bortezomib …
Proteasome inhibitors interrupt the activation of Non-Canonical NF-κB signaling pathway and induce cell apoptosis in Cytarabine-Resistant HL60 cells
Over half of older patients with acute myeloid leukemia (AML) do not respond to cytotoxic
chemotherapy, and most responders relapse because of drug resistance. Cytarabine is the …
chemotherapy, and most responders relapse because of drug resistance. Cytarabine is the …
Bortezomib Interacts Synergistically with Belinostat to Induce Apoptosis In Human Acute Myeloid and Lymphoid Leukemia Cells
Y Dai, S Chen, L Wang, XY Pei, L Kramer, P Dent… - Blood, 2010 - Elsevier
Abstract 3266 Previous studies have demonstrated interactions between histone
deacetylase (HDAC) and proteasome inhibitors (PIs) in multiple myeloma, NHL, and CLL …
deacetylase (HDAC) and proteasome inhibitors (PIs) in multiple myeloma, NHL, and CLL …
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
C Freiburghaus, VK Emruli, A Johansson… - BMC cancer, 2018 - Springer
Background The addition of high-dose cytarabine to the treatment of mantle cell lymphoma
(MCL) has significantly prolonged survival of patients, but relapses are common and are …
(MCL) has significantly prolonged survival of patients, but relapses are common and are …
Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells
KY Chong, CJ Hsu, TH Hung, HS Hu… - Cancer Biology & …, 2015 - Taylor & Francis
Multiple drug resistance (MDR) is a major obstacle to attenuating the effectiveness of
chemotherapy to many human malignancies. Proteasome inhibition induces apoptosis in a …
chemotherapy to many human malignancies. Proteasome inhibition induces apoptosis in a …
High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors
Proteasome inhibitors such as bortezomib exhibit clinical efficacy in multiple myeloma, but
studies in acute myeloid leukemia (AML) have been disappointing to date. The apparent …
studies in acute myeloid leukemia (AML) have been disappointing to date. The apparent …
[HTML][HTML] Proteasome Inhibitor Bortezomib Induces Apoptosis in Prednisone-Resistant Childhood Acute Lymphoblastic Leukemia Cells.
S Junk, M Lauten, G Cario, N Wittner, M Schrappe… - Blood, 2009 - Elsevier
Abstract Abstract 991 Poster Board I-13 The response to initial glucocorticoid therapy in
childhood acute lymphoblastic leukemia (ALL) reliably predicts the response to multi-agent …
childhood acute lymphoblastic leukemia (ALL) reliably predicts the response to multi-agent …
Investigating the mechanisms underlying Bortezomib resistance
K Zafeiropoulou, G Kalampounias, S Alexis… - bioRxiv, 2023 - biorxiv.org
Proteasome inhibitors such as Bortezomib, represent an established type of targeted
treatment for several types of hematological malignancies, including multiple myeloma …
treatment for several types of hematological malignancies, including multiple myeloma …
The role of bortezomib in the treatment of acute lymphoblastic leukemia
MF Zahid - Future Oncology, 2016 - Future Medicine
COmmEntaRY Zahid future science group more patient-centered, individually tailored and
risk-adapted treatment protocols can be developed based on the biology of each patient's …
risk-adapted treatment protocols can be developed based on the biology of each patient's …
Bortezomib induces a pro-apoptotic Bcl-2 family protein expression profile necessary to kill therapy-resistant B cell non-Hodgkin's lymphoma (B-NHL)
S Olejniczak, F Hernandez-Ilizaliturri, J Blickwedehl… - Cancer Research, 2008 - AACR
Abstract 4383 Cancer cells, including B-cell lymphoproliferative disorders, sculpt their
phenotype in an attempt to escape not only immune-surveillance but also evade the anti …
phenotype in an attempt to escape not only immune-surveillance but also evade the anti …